Adverum Biotechnologies (ADVM) Begins New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results
May 28, 2020 4:01 PM EDT-- INFINITY is a randomized, active comparator-controlled trial --
-- INFINITY trial initiated for patients with diabetic macular edema, the most common cause of vision loss in people with diabetic retinopathy --
-- Positive interim clinical data recently presented for ADVM-022 in OPTIC Phase 1 trial for wet AMD; data from all four cohorts expected to be presented by year-end --
-- Company to host conference call today at 1:30 pm PDT / 4:30 pm EDT --
REDWOOD CITY, Calif., May 28, 2020 (GLOBE NEWSWIRE) --... More
